Healthcare provider perspectives on HPV vaccinations at ages 9–10 in the United States

This study investigated health care providers' (HCPs') attitudes and experiences with initiating HPV vaccination at 9-10 y old instead of 11-12 y old. We conducted a cross-sectional online survey with 500 US HCPs who reported recommending and/or administering HPV vaccination to pediatric patients, recruited from a membership-based panel. The survey focused on providers' experiences with, and attitudes toward, routine HPV vaccination at age 9-10. Participants included pediatricians (n = 175), family medicine physicians (n = 175), nurse practitioners (n = 75), and physician assistants (n = 75). HCPs were mostly female (56%), white (79%), with a mean age of 43 y. HCPs reported <i>mentioning</i> the HPV vaccine to boys and girls before age 11 72% and 77% of the time, respectively, but <i>recommending</i> it prior to age 11 less frequently (38% and 51% of the time). Few HCPs (11%) reported introducing the vaccine at the same visit at which it was given; 36% reported multiple discussions before acceptance. A substantial proportion of HCPs (23%) would not administer HPV vaccine when children were <11 y old, even if asked by parents. HCPs reported that a majority of parents who were offered HPV vaccination for their children at 9-10 y of age accepted. HCPs identified benefits of earlier vaccination; the top three were improving on-time completion, completion prior to other adolescent vaccines and increased opportunities to vaccinate. Top concerns included parent misconception about the duration of protection and difficulty explaining HPV vaccination to a younger child. Findings suggest most HCPs would support earlier HPV vaccination and see potential for improved completion.

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2025-09-22
DOI
https://doi.org/10.1080/21645515.2025.2561455
Citations
4
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
5.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Healthcare provider perspectives on HPV vaccinations at ages 9–10 in the United States

Gregory D. Zimet, Rishi P. Verma, Jordana K. Schmier, Amanda F. Dempsey et al.
4 citations
Human Vaccines & Immunotherapeutics
Cervical Cancer and HPV Research
5.42
article

Healthcare provider perspectives on HPV vaccinations at ages 9–10 in the United States

Gregory D. Zimet, Rishi P. Verma, Jordana K. Schmier, Amanda F. Dempsey, Kunal Saxena, Rebecca Martinez
article en
4 citations

Abstract

This study investigated health care providers' (HCPs') attitudes and experiences with initiating HPV vaccination at 9-10 y old instead of 11-12 y old. We conducted a cross-sectional online survey with 500 US HCPs who reported recommending and/or administering HPV vaccination to pediatric patients, recruited from a membership-based panel. The survey focused on providers' experiences with, and attitudes toward, routine HPV vaccination at age 9-10. Participants included pediatricians (n = 175), family medicine physicians (n = 175), nurse practitioners (n = 75), and physician assistants (n = 75). HCPs were mostly female (56%), white (79%), with a mean age of 43 y. HCPs reported <i>mentioning</i> the HPV vaccine to boys and girls before age 11 72% and 77% of the time, respectively, but <i>recommending</i> it prior to age 11 less frequently (38% and 51% of the time). Few HCPs (11%) reported introducing the vaccine at the same visit at which it was given; 36% reported multiple discussions before acceptance. A substantial proportion of HCPs (23%) would not administer HPV vaccine when children were <11 y old, even if asked by parents. HCPs reported that a majority of parents who were offered HPV vaccination for their children at 9-10 y of age accepted. HCPs identified benefits of earlier vaccination; the top three were improving on-time completion, completion prior to other adolescent vaccines and increased opportunities to vaccinate. Top concerns included parent misconception about the duration of protection and difficulty explaining HPV vaccination to a younger child. Findings suggest most HCPs would support earlier HPV vaccination and see potential for improved completion.

Human Vaccines & ImmunotherapeuticsVol. 21(1)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Clinical Research Consulting (US)
Openalex Percentile: Top 4%
Cervical Cancer and HPV Research
5.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.